The Federal Commission for the Protection against Sanitary Risks (Cofepris) granted health registration to Paxlovid (nirmatrelvir/ritonavir)from the laboratory Pfizer, for the treatment of COVID-19 in adults who do not require supplemental oxygen and are at increased risk of progression to serious illness.
Video: Harvey Weinstein Hospitalized for COVID-19 and Double Pneumonia
He Committee on New Molecules (CMN)) thoroughly evaluated the drug, and specialists from Cofepris They carried out a rigorous technical analysis.
These studies concluded that Paxlovid meets the requirements of the necessary quality, safety and effectiveness.
Thanks to these results, Cofepris allowed open marketing of the first drug intended to prevent hospitalizations and mortality from COVID-19 in Mexico, positioning itself as one of the first regulatory agencies to take this step.
Paxlovid It already has the approval of important international regulatory entities, such as the U.S. Food and Drug Administration (FDA), Health Canada, European Medicines Agency (EMA) and Latin American authorities such as Anvisa in Brazil and Anamed in Chile. The authorization in Mexico represents a significant advance in the fight against the pandemic, according to the Cofepris.
Paxlovid requires a prescription
This treatment requires a medical prescription and must be administered under strict medical supervision. Cofepris It emphasizes the importance of avoiding indiscriminate use and self-medication, and urges health professionals to carefully evaluate risk factors and use.
Besides, the Cofepris Cofepris asks the population to report any adverse events and denounce the irregular sale of the drug to protect public health. Cofepris reminds that Paxlovid does not replace the authorized vaccines against COVID-19 and should not be used without medical advice.
With this approval, Cofepris reaffirms its commitment to proactive and collaborative regulation, working hand in hand with the manufacturing laboratory to expand the available treatment options and continue to advance in the fight against COVID-19.
Recommended stories:
With information from N+
HAVJ
